Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo

Completed 22 enrolled Yale University

RandomizedParallel-groupTriple-blindTreatment

Summary

This study will test the effectiveness of the combination of Naltrexone and Bupropion relative to placebo for reducing binge eating in persons with obesity and binge eating disorder.

Timeline

Start: 2014-12
Primary completion: 2016-09
Completion: 2016-09

Outcome

Missed primary endpoint

paper changes with NB did not differ significantly from those with placebo. PMID 33218742 ↗

Publications

Grilo CM, Lydecker JA, Morgan PT, Gueorguieva R. Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study. Clin Ther. 2021 Jan;43(1):112-122.e1. doi: 10.1016/j.clinthera.2020.10.010. Epub 2020 Nov 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bupropion	Small molecule	300 mg	—
Subject	Naltrexone	Small molecule	50 mg	—